On October 18, 2023 Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, reported the grant of stock options to purchase 60,000 shares of its common stock to one new employee (Press release, Verastem, OCT 18, 2023, View Source [SID1234636119]). The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $7.65 per share, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on October 12, 2023. The stock options to purchase 30,000 shares of common stock that were granted to the one new employee will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee’s date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date. The stock options to purchase 30,000 shares of common stock that were granted to one new employee will vest upon the achievement of a certain commercial milestone, provided the employee continues to serve as an employee of or other service provider to Verastem Oncology on such vesting date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 18, 2023 Patrys reported that data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of high grade glioma will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Brain Cancer in Minneapolis, Minnesota (Press release, Patrys, OCT 18, 2023, View Source [SID1234636117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "A novel lupus-associated antibody that inhibits the growth of aggressive high-grade glioma orthotopic xenografts and enhances radiotherapy via a unique mechanism" describes research conducted by Professor Terrance Johns from the Telethon Kids Cancer Centre in Perth confirming the single agent activity of both PAT-DX1 and PAT-DX3 in animal models of high grade glioma, as well as the significant survival benefits from combining PAT-DX1 with a therapeutic dose of radiation.

Professor Terrence Johns said:

"I am excited to present our findings with PAT-DX1 and PAT-DX3 at the AACR (Free AACR Whitepaper) Special Conference in Cancer Research: Brain Cancer. Through my partnership with Patrys we have demonstrated both antibodies reach and inhibit the growth of intracranial brain cancers in rodent models. Significantly, we have shown that PAT-DX1 dramatically enhances the activity of radiotherapy, which is the standard of care for many forms of brain cancer."

On October 18, 2023 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the pricing of its underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share (Press release, Ultragenyx Pharmaceutical, OCT 18, 2023, View Source [SID1234636115]). In addition, in lieu of issuing common stock to certain investors, the company is offering pre-funded warrants to purchase 1,666,722 shares of its common stock at a purchase price of $29.999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The aggregate gross proceeds to the company from this offering is expected to be $300 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,500,000 shares of the company’s common stock at the public offering price, less the underwriting discount.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is expected to close on or about October 23, 2023, subject to satisfaction of customary closing conditions. J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became automatically effective on February 12, 2021. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at prospectus- [email protected]; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]; BofA Securities, NC1-002-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; and Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at [email protected] or by telephone at (833) 297-2926.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On October 18, 2023 Supernus Pharmaceuticals presented its corporate presentation (Presentation, Supernus, OCT 18, 2023, View Source [SID1234636114]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 18, 2023 Prescient Therapeutics (ASX:PTX) reported that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting in December (Press release, RAPT Therapeutics, OCT 18, 2023, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-two-flx475-presentations-society [SID1234636112]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The meeting is the largest and most comprehensive hematology conference in the world.

Prescient Therapeutics managing director and CEO, Steven Yatomi-Clarke, said, "It is a huge honour to have our abstract presented at the world’s most prestigious haematology conference. This is a validation of the quality and relevance of the clinical data we are generating in T-cell lymphomas, which is an area of unmet clinical need. It is also a testament to the hard work by the Prescient team and our clinical collaborators.

"Prescient looks forward to presenting this data at ASH (Free ASH Whitepaper) and will release this data to the market concurrently."